Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Daniel A McBride , Timothy M Markman , Jackson J Liang , et al Added: 3 years ago
The left atrial appendage (LAA) is a trabeculated structure with variable anatomy comprised of pectinate muscle, which grows out of the primary atrium before the left atrium (LA) develops. This outcropping joins the venous component of the LA by way of a bottlenecked junction, in contrast to the anatomy of the right atrial appendage which, although trabeculated, joins the atrium via a wider neck… View more

Electrophysiology & Arrhythmia

Intervention
Identification of Patients at Risk of Stroke From Atrial Fibrillation
Author(s): Raymond B Fohtung , Michael W Rich Added: 3 years ago
Atrial fibrillation (AF) is the most common clinically significant arrhythmia, with an overall prevalence of approximately 1 % in the general population.1 An estimated 2.3 million adults in the US have AF, and this number is projected to increase to 5.6 million by 2050.1 The most clinically important complication from AF lies in the risk for cardiac thrombus formation and systemic embolism… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
Author(s): Praveen Rao , Olusegun Olusesi , Mitchell Faddis Added: 3 years ago
It is presumed that the pathogenesis of stroke in atrial fibrillation (AF) patients is due to embolization of thrombus from the left atrium. Within the left atrium, the left atrial appendage is the predominant site of thrombus formation. In a study of 233 patients with new onset AF of greater than 48 hours in duration who were not anticoagulated, left atrial appendage thrombus was present in 15 %… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
Author(s): Stefan H Hohnloser Added: 3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and is associated with a five-fold increase in the risk of stroke and embolism.1 Oral anticoagulation (OAC) with warfarin reduces stroke by two-thirds compared with no treatment.1–3 Compared with aspirin, OAC reduces the risk of stroke by 45% and reduces cardiovascular events by 29%.4 However, it increases the risk of major bleeding… View more

Anticoagulation

Standards & Guidelines
Best Practices in Pharmacotherapy for Acute Coronary Syndromes
Author(s): Robert Barcelona Added: 1 year ago

Anticoagulation

MI/ACS
Author(s): A Bajpai , A John Camm , I Savelieva Added: 3 years ago
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is characterized by unco-ordinated atrial activation with consequent loss of atrial mechanical function. In developed nations, the number of men and women affected by AF is projected to more than double over the next two decades. Despite major advances in its management, AF remains a significant cause of cardiovascular… View more

Electrophysiology & Arrhythmia
Transcatheter LAA Closure
Author(s): Chirag Bavishi Added: 11 months ago

Vascular Disease and Surgery

Electrophysiology & Arrhythmia
Author(s): Roy Arjoon , Ashley Brogan , Lissa Sugeng Added: 3 years ago
Cardiovascular medicine has undergone a momentous change over the past 2 decades with the development of percutaneous transcatheter interventions for structural heart disease. This field has the greatest growth in interventional cardiology for the foreseeable future.1–3 The number of patients with acquired valvular heart disease and adult congenital heart disease will only rise in the future as… View more

Imaging & Diagnostics

Intervention
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 7 months ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
ESC 23: COP-AF: Colchicine for Perioperative AF
Author(s): David Conen Added: 7 months ago
ESC 2023 — Dr David Conen (McMaster University, CA) joins us onsite for a short interview focussing on the findings from the COP-AF trial (NCT03310125). COP-AF (Population Health Research Institute) aimed to assess if oral colchicine reduced the incidence of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery. 3209… View more

Electrophysiology & Arrhythmia